EIT Pharma Closes Oversubscribed $35M Series A to Advance Lonafarnib Through FDA Review for Chronic Hepatitis D

EIT Pharma closed a $35 million Series A financing round on August 31, 2026 — oversubscribed — with Propel Bio Partners leading and Good Ventures, Arrowtown, and others participating, per the company's August 31 news release on PR Newswire.

The FDA had accepted EIT Pharma's New Drug Application for lonafarnib on August 11, per the company's separate August 11 PR Newswire release.

Lonafarnib is an investigational, first-in-class oral therapy candidate for chronic hepatitis D (CHD), a serious, life-threatening liver disease caused by the hepatitis D virus in patients who already carry hepatitis B. According to the company's August 31 release, no FDA-approved oral therapies for CHD currently exist in the United States.

The clinical foundation behind the NDA is the D-LIVR Phase 3 study, which enrolled more than 400 participants across 21 countries, per the August 31 release.

Proceeds are designated for continued FDA review activities for lonafarnib, future manufacturing and commercial readiness steps subject to regulatory approval, and advancement of EIT Pharma's broader infectious disease pipeline, per the company's release.

Dr. Leen Kawas, Chief Executive Officer of EIT Pharma, stated: "This oversubscription of this round is a validation of EIT Pharma's founding belief that advancing important medicines is about recognizing unrealized potential and assembling the scientific, clinical, regulatory, and commercial expertise to turn that potential into a treatment for patients. This new capital allows us to continue advancing lonafarnib through the review process and, subject to FDA approval, prepare to bring it to patients."

Richard Kayne, General Partner of Propel Bio Partners, added: "EIT Pharma pairs a differentiated, late-stage asset with a team experienced in moving complex programs through development and regulatory review."

EIT Pharma commenced operations in January 2025, per the release. Lonafarnib came to EIT Pharma through the 2024 bankruptcy of Eiger BioPharmaceuticals in a court-supervised sale. Kawas is a co-founder and managing general partner of Propel Bio Partners, the round's lead investor — making the lead investor and the CEO the same founding figure.

EIT Pharma is privately held and unlisted. No share price, market cap, or dilution figures appear in the primary release, so none are reported here.

The company's stated priorities are navigating the ongoing FDA review of the lonafarnib NDA and, if approved, executing on manufacturing and commercial readiness, per the August 31 release.